These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1120 related articles for article (PubMed ID: 22633802)

  • 1. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
    Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F
    Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
    Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
    J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series.
    Bertz S; Denzinger S; Otto W; Wieland WF; Stoehr R; Hofstaedter F; Hartmann A
    Histopathology; 2011 Oct; 59(4):722-32. PubMed ID: 22014053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.
    Culpan M; Turan T; Ozkanli SS; Zenginkinet T; Kazan O; Ucar T; Atis G; Caskurlu T; Yildirim A
    J Cancer Res Ther; 2021; 17(2):434-442. PubMed ID: 34121689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
    Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
    Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of bladder cancer patients with disseminated tumour cells in bone marrow.
    Retz M; Rotering J; Nawroth R; Buchner A; Stöckle M; Gschwend JE; Lehmann J
    Eur Urol; 2011 Aug; 60(2):231-8. PubMed ID: 21190793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer.
    Otto W; Rubenwolf PC; Burger M; Fritsche HM; Rößler W; May M; Hartmann A; Hofstädter F; Wieland WF; Denzinger S
    BMC Cancer; 2012 Oct; 12():459. PubMed ID: 23043286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer.
    Asakura T; Takano Y; Iki M; Suwa Y; Noguchi S; Kubota Y; Masuda M
    J Urol; 1997 Aug; 158(2):385-8. PubMed ID: 9224308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.